New Phase 2a CMT trial results are in. NMD Pharma shares details.
CMT Community Helps Achieve a Major Research Milestone with NMD Pharma
What happens when the CMT community takes action and participates in CMT research? NMD Pharma answers the question.
Augustine Therapeutics Begins New CMT Trial
CMT news out of Belgium: Augustine Therapeutics has officially dosed the first participant in a...
Augustine Therapeutics – AGT-100216
The Phase I trial will focus on safety, tolerability, and pharmacokinetics (how the drug moves...
Actio Biosciences – ABS-0871
The Phase I study is a randomized, double-blind, placebo-controlled trial evaluating the safety, tolerability, and...
Actio Biosciences Doses First Participant in Phase I Clinical Trial | Future Phase Ib Clinical Trial to Focus on CMT2C
CMTA-STAR Alliance Partner Actio Biosciences has announced that the first participant has been dosed in its Phase...
NMD Pharma – SYNAPSE-CMT
This Phase 2a study aims to evaluate the efficacy, safety and tolerability of NMD670 vs...
SENSE HSN1 Clinical Trial
With $354,826 in CMTA funding, the SENSE Trial is an HSN1 clinical trial investigating a potential treatment for hereditary sensory neuropathy type 1, with active participation now complete and final data analysis underway.
Applied Therapeutics – INSPIRE
This study is designed to assess the efficacy and safety of AT-007 treatment in patients...
CMTA | STAR Awards $354,826 For Charcot-Marie-Tooth Clinical Trial
CMTA-STAR has awarded $354,826 to support a clinical trial evaluating L-serine in patients with Hereditary Sensory Neuropathy 1, a rare form of CMT. Led by Dr. Mary Reilly at University College London, the study will assess disease progression using MRI muscle fat fraction as a primary outcome measure, advancing clinical trial readiness for inherited neuropathies.
